A novel topical therapy for Atopic Dermatitis through development of LXR agonists
This project will deliver a novel topical therapy for Atopic Dermatitis (AD). AD is a common, chronic, inflammatory skin disease. A great body of evidence supports Liver X Receptors (LXRs) as a therapeutic target for AD. The DERMAL project will perform lead selection and preclinical development based on a newly identified chemical series of LXR agonists. This project will produce formulated lead compounds that will be ready for clinical trials within 18 months after completion of this project.
3 439 180.00€
Pharmaceutical Products / Drugs
Drug delivery and other equipment (including kidney dialysis machines)